Pharmacoeconomic issues in onychomycosis

British Journal of Dermatology, Supplement

Volumn 149, Issue 65, 2003, Pages 19-22

  Lambert, J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Amorolfine; Onychomycosis; Pharmacoeconomics

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MONOTHERAPY; ONYCHOMYCOSIS; PRIORITY JOURNAL; TOPICAL TREATMENT;

EID: 0242487620     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.149.s65.3.x     Document Type: Conference Paper

References (3)

1. Anderson P, Lloyd A. Outcomes research and health economics. In: Di Giovanna, I. Hayes, G. eds. Principles of Clinical Research. Petersfield, Philadelphia: Wrightson Biomedical Publishing Ltd. 2001: p. 291-316.
2. Baran R et al. A randomised trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycosis affecting the matrix region. Br J Dermatol 2000; 142: 1177-83.
3. Lecha M et al. An open-label, muticenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole in the treatment of severe toenail onychomycosis. Current Therapeutic Res 2002; 63: 366-79.